FDA Recall Terminated

Enteryx Injector Single Pack Order Number: M00572650-US and M00572630 -OUS

Recall: Z-0041-06 · Initiated September 23, 2005

Recall

Recall Number
Z-0041-06
Event Number
33529
Firm
Boston Scientific Corporation
FEI Number
3001451463
Product Code
FBK
Status
Terminated
Root Cause
Other
Initiated
September 23, 2005
Posted
October 28, 2005
Terminated
October 24, 2006
Address
1 Boston Scientific Pl, Natick, MA, 01760-1536

Description

Enteryx Injector Single Pack Order Number: M00572650-US and M00572630 -OUS

Reason

Incorrect implantation may cause serious health complications

Action

Boston Scientific issued Recall notification by FED'X on 9/23/05 as follows Customers/ Hospital Account / Distributors: A Recall Notification Package will be sent to the risk manager of each hospital account via FedEx. This package contains a Recall Notification Letter, instructions on how to return product, a Recall Verification Form, and a Physician Letter that provides recommendations of patient follow-up. . Physicians Trained in the Enteryx Procedure: All physicians that attended the physician training program sent, via FedEx, a Physician Letter notifying them of the voluntary recall and providing them with firm recommendations on patient follow-up. In addition a copy of the Patient Letter and Patient Phone Script will be provided to assist in their communication to the patient. Patient Letter / Patient Phone Script: A letter and phone script, from the physician to the patient, will be provided to the physician to assist in the physician's communication to patient. The letter informs the patient of the recall and asks them to contact their physician and the Patient Phone Script provides a template to initiate a discussion with the patient. Physicians Participating in Post Approval Studies: All physicians that are participating in post approval studies will be sent, via FedEx, a Physician Letter notifying them of the voluntary recall and providing them with firm's recommendations on patient follow-up. In addition a copy of the Patient Letter and Patient Phone script will be provided to assist in their communication to the patient. Internal Review Boards (IRBs): All IRBs that are participating in post approval studies will be sent, via FedEx, a IRB Letter and the Physician Letter notifying them of the voluntary recall and providing them with firm's recommendations on patient follow-up. In addition a copy of the Patient Letter and Patient Phone Script will be provided. Boston Scientific has posted the recall to their website:http://www

Distribution

Nationwide :

Quantity

M00572650=4080 Single; M00572630 =217 Single